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In this issue of Cancer Cell, Gannon and colleagues create genetically engineered mice to test the role phos-
phorylation plays in the modification of one serine long thought to play a critical role in controlling the activity
of MDM2, one of p53’s main negative regulators.The tumor suppressor p53 is activated
by numerous stressors and results in
expression or repression of hundreds of
genes that elicit a broad range of biolog-
ical responses culminating in effective
tumor suppression. However, p53 acti-
vation must be controlled with exquisite
care because as little as a 2-fold reduc-
tion in its activity can cause radio resis-
tance and increased tumorigenicity
(Bondet al., 2004;Wanget al., 2009). Con-
versely, a 2-fold increase in p53 activity
such as in p537KR/7KR mice (a knock-
in model in which seven conserved
C-terminal lysine residues were replaced
by arginine) can lead to myeloblation and
death by heart failure (Wang et al., 2011).
Ubiquitin-mediated proteolysis is cen-
tral to controlling p53’s protein level
and activity. In unstressed cells, the
E3 ubiquitin-ligase MDM2 recruits E2
ubiquitin-conjugating enzymes to trans-
fer ubiquitins onto p53 and MDM2 itself,
resulting in proteasomal degradation of
both proteins. MDM4 (also known as
MDMX), a protein related to MDM2 but
lacking intrinsic E3 ubiquitin-ligase
activity, hetero-oligomerizes with MDM2
to modulate MDM20s E3 ligase activity
(Wade et al., 2010). MDM2 and MDM4
play non-overlapping and tissue-specific
roles to precisely control p53 levels and
activity (Wade et al., 2010). DeletingMdm2 typically elicits a more extreme
phenotype than deleting Mdm4, but
eliminating p53 rescues both. This
demonstrates that both MDM2 and
MDM4 are critical nodes in p53 regula-
tion. MDM2 is a p53-induced gene, and
in vitro studies show that increasing
MDM2 abundance can attenuate p53
activation, leading p53 to return to low
basal levels upon resolution of the
inducing stress. The importance of this
negative feedback loop for p53 regulation
in vivo in different tissues remains unclear.
Correct temporal control of p53
responses is critical, but how this is
achieved in vivo remains to be resolved.
Posttranslational modifications play crit-
ical roles in p53 regulation, so the
residues of p53, MDM2, and MDM4
that are modified by damage-activated
kinases, phosphatases, and other modi-
fying enzymes are prime candidates
for temporal regulators. The acceptable
thresholds for p53 regulation have been
dramatically revealed by studies showing
that mice heterozygous for Mdm2 or
Mdm4, with reduced expression of
Mdm2 or Mdm4, or with blocked post-
translational modification at damage-
modifiable residues have profoundly
altered radiation responses (Bondar and
Medzhitov, 2010; Wang et al., 2009).
Ionizing radiation activates DNAdamage-activated kinases such as ATM
and CHK2, resulting in phosphorylation
of multiple residues on MDM2, MDM4,
and p53 (Wade et al., 2010). Studies in
human cancer cell lines first suggested
that preventing MDM2 Ser395 (mouse
Ser394) phosphorylation could impair its
damage-dependent degradation and
consequently attenuate p53 activation
(Maya et al., 2001). DNA damage also
induces MDM4 phosphorylation at serine
341,367, and 402, resulting in its MDM2-
dependent degradation. Mice expressing
Mdm4 3SA, anMDM4mutant with alanine
substitutions at these three positions, are
remarkably resistant to ionizing radiation
due to attenuated radiation-induced p53
responses in the hematopoietic system
but are very sensitive to c-Myc induced
lymphomagenesis (Wang et al., 2009).
Both phenotypes result from a modest
2-fold reduction in p53 basal and induced
activity. These data suggest the impor-
tance of regulating MDM4 stability in vivo
for controlling p53 activity.
In this issue of Cancer Cell, Gannon
et al. (2012) demonstrate the importance
of MDM2 Ser394 phosphorylation in
regulating the responses of mice to
irradiation by making S394A (non-phos-
phorylatable) and S394D (phosphomi-
metic) mutations. They show that this
amino acid can swing the penduluml 21, May 15, 2012 ª2012 Elsevier Inc. 595
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dinary radio resistance. Thus, just as
shown for Mdm43SA/3SA and p537KR/7KR
mice, it is not DNA damage caused by
irradiation that induces lethality; rather, it
is the p53 response that is critical. Impor-
tantly, and in contrast to Mdm43SA/3SA
mice that do not display increased
lymphomagenesis following irradiation,
65% ofMdm2S394A/S394Amice developed
spontaneous lymphomas in 24 months,
a rate similar to that in p53+/ animals.
These data indicate that proper MDM2
Ser394 phosphorylation contributes to
effective p53-mediated tumor sup-
pression. The mechanistic differences
underlying the variance in lymphomagen-
esis remain unclear, though it appears
that p53 levels are reduced significantly
more in Mdm2S394A/S394A mice than in
Mdm43SA/3SA mice. Interestingly, the
phenotype observed by Gannon et al.
(2012) were not associated with differ-
ences in MDM2 stability, suggesting that
another mechanism may be at play.
Given the attenuated p53 responses
in Mdm2S394A/S394A mutants, would con-
stitutive phosphorylation of this residue
cause persistent p53 activation and
consequent embryonic lethality similar to
Mdm2 and Mdm4 null mice? Gannon
et al. (2012) address this question by
substituting Ser394 with aspartic acid
(S394D) to create a phosphomimetic
mutation. Surprisingly, Mdm2S394D/S394D
mice were born at Mendelian ratios, and
p53 baseline level and activity were
similar to those in wild-type mice. The
only difference appeared to be that the
duration of irradiation-induced p53 acti-
vation was extended in Mdm2S394D/S394D
cells. The authors posit that removal of
damage-induced Ser394 phosphoryla-
tion may be critical for correct temporal
regulation of p53 responses to radiation.
Interestingly, the p53-induced phospha-
tase WIP1 can dephosphorylate MDM2
Ser395 and is overexpressed in breast
and other cancers with wild-type p53, so
WIP1 may play a role in the attenuation
response (Lu et al., 2007). Further studies
are needed to investigate this intriguing
idea.596 Cancer Cell 21, May 15, 2012 ª2012 ElsThe surprisingly modest phenotype
of Mdm2S394D/S394D mice could be ex-
plained in several ways. First, p53 activa-
tion may require modification of more
MDM2 residues than just Ser394 as sug-
gested by a recent study in human
cancer cells (Cheng et al., 2011). A
second possibility is that replacing Ser
by Asp does not provide a faithful mimic
of phosphorylation. The side-chain
carboxyl groups in Asp and glutamic
acid (Glu) exhibit a 1 charge at physio-
logic pH, while a phosphate group carries
1.5 charges. Furthermore, the atomic
radius of a phosphate group is about
three times that of the carboxyl side-
chain of Asp or Glu. These differences
may be critical when considering the
mechanisms by which MDM2 Ser394
may actually impact MDM2 E3 ubiqui-
tin-ligase activity.
How could substitutions of the single
C-terminal residue Ser394 cause such
dramatic phenotypes? Recent biochem-
ical studies in human cancer cell lines
suggest that mutations in six MDM2
C-terminal phosphorylation sites (S386,
S395, S407, T419, S425, and S429;
MDM2 6A) may impact MDM2 oligomeri-
zation and affect E3 ligase function
(Cheng et al., 2011). Consistent with the
Mdm2S394A/S394A results, the MDM2 6A
mutant also exhibited increased E3
ubiquitin-ligase activity toward p53.
These observations may be reconciled
by a phosphorylation-induced structural
alteration model, as observed recently
for the E3 ubiquitin-ligase CBL (Dou
et al., 2012). CBL regulates the stability
of growth factor-activated receptor tyro-
sine kinases. In the absence of growth
factor, CBL adopts an auto-inhibited
conformation. However, upon growth
factor signaling, CBL undergoes a con-
formational change that is initiated by
phosphorylation of a single tyrosine
residue (Y371). This enables CBL to better
bind and position an E2 so that it can
ubiquitylate its receptor tyrosine kinase
substrate, resulting in a 1,400-fold
increase in ubiquitylation activity (Dou
et al., 2012). However, for MDM2,
perhaps lack of phosphorylation enablesevier Inc.E2 recruitment for the purpose of p53
degradation whereas phosphorylation
may create a conformational change that
prevents this. Alternatively, MDM2 S395
phosphorylation by ATM may activate
p53 by increasing MDM2 binding of p53
mRNA which reportedly increases p53
mRNA translation (Gajjar et al., 2012).
The importance of good hypotheses is
that they suggest experiments to test
them, and we suspect these will con-
stitute the next phase of deciphering
mechanisms of p53 regulation.ACKNOWLEDGMENTS
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